CFH rs6792954: Understanding Genetic Associations with AMD
The rs6792954 variant is a single nucleotide polymorphism located within the CFH gene, which provides instructions for making a protein that regulates the immune system. Research has identified this variant as being statistically associated with an increased risk of developing age-related macular degeneration (AMD) in certain populations.
What each genotype means
Typical AMD genetic risk
You carry two copies of the common C allele at rs6792954 in the CFH locus. Research indicates that this genotype is associated with a baseline susceptibility to age-related macular degeneration (AMD) relative to this specific marker. Because overall AMD risk is influenced by multiple genetic loci and lifestyle factors like smoking and diet, carrying this genotype does not guarantee eye disease.
Carried by approximately 30% to 40% of individuals of European ancestry, representing the most common homozygous genotype.
Slightly altered AMD susceptibility
You carry one copy of the C allele and one copy of the T allele at rs6792954. Published association studies suggest this genotype reflects an intermediate risk profile for age-related macular degeneration compared to homozygous genotypes. The evidence for this specific variant is limited and largely captured via broader linkage disequilibrium patterns within the complement factor H gene cluster.
Observed in roughly 45% to 50% of European populations and common across global cohorts.
Altered complement locus susceptibility
You carry two copies of the T allele at rs6792954 in the CFH region. In genetic association studies, homozygosity for this allele is associated with a modestly altered statistical susceptibility to age-related macular degeneration. Current scientific evidence regarding this specific single-nucleotide variant is limited, and carrying this genotype is not a medical diagnosis of retinal disease.
Carried by roughly 12% to 20% of individuals of European ancestry.
What is rs6792954?
The rs6792954 variant is a specific change in the DNA sequence of the CFH gene. In genetics, a single nucleotide polymorphism (SNP) like rs6792954 represents a variation at a single position in the genome. This variant is located within the CFH locus, a region of chromosome 1 that has been extensively studied for its role in eye health. Scientists track these variations to understand how subtle differences in our genetic code might influence the likelihood of developing complex, late-onset conditions. Because rs6792954 is a common variant, it is found in a significant portion of the population, making it a frequent subject of genome-wide association studies (GWAS) aimed at mapping the genetic architecture of common diseases.
The Role of the CFH Gene
The CFH gene encodes complement factor H, a critical protein in the body's complement system. This system is a part of the innate immune response that helps clear pathogens and damaged cells. Complement factor H acts as a regulator, preventing the complement system from becoming overactive and damaging healthy tissues. When the CFH gene functions normally, it helps maintain the delicate balance of inflammation in the eye. However, variations in this gene can alter the production or function of the factor H protein. Research suggests that impaired regulation of the complement pathway may contribute to the accumulation of deposits known as drusen under the retina, which is a hallmark of age-related macular degeneration (AMD).
Research and Evidence Strength
The association between the CFH gene and AMD is well-documented in scientific literature. Multiple studies have identified variants in this region as significant risk factors for the development of AMD. While the evidence linking the CFH locus to AMD is strong, the specific contribution of individual variants like rs6792954 can vary. It is important to note that AMD is a multifactorial condition, meaning it is influenced by a combination of genetic factors, environmental exposures, and lifestyle choices such as smoking. The evidence for any single variant is rarely deterministic; rather, it indicates a statistical increase in risk. Because many different variants across the CFH gene and other loci contribute to disease risk, the clinical utility of testing for a single SNP remains limited.
Population Frequency
The frequency of the rs6792954 variant varies across different ancestral groups. In European populations, the minor allele frequency (MAF) is typically observed between 0.35 and 0.45. This high frequency indicates that the variant is common rather than rare. Because it is so prevalent, researchers must account for this background frequency when calculating the statistical risk associated with the variant. It is also important to recognize that genetic associations observed in one population may not be identical in others due to differences in genetic background and environmental interactions. Consequently, the impact of this variant on disease risk is best understood within the context of broader genetic studies that include diverse ancestral cohorts.
Interpreting Your Genetic Information
If you have information about your genotype for rs6792954, it is essential to view it as one small piece of a much larger puzzle. Genetic variants associated with complex diseases like AMD do not provide a diagnosis or a guarantee of future health. Many people with high-risk genotypes never develop the condition, while others without these variants may still be affected. This information should not be used to make medical decisions or to predict personal health outcomes. If you are concerned about your vision or your risk for eye disease, the most effective step is to consult with an eye care professional, such as an ophthalmologist or optometrist. They can provide comprehensive screenings and personalized advice based on your clinical history, which is far more informative than any single genetic marker.
How common is this variant?
The rs6792954 variant is common, with a minor allele frequency (MAF) of approximately 0.35 to 0.45 in European populations.
Frequently asked questions
Does having this variant mean I will get AMD?
No, having a specific genotype for this variant does not mean you will develop AMD. AMD is a complex disease influenced by many genetic and environmental factors, and this variant only represents a statistical association with risk.
Should I get tested for CFH variants?
Genetic testing for common variants like those in the CFH gene is generally not recommended for the general public. Clinical diagnosis of AMD is based on eye examinations by a professional, not on genetic testing.
What can I do to lower my risk of AMD?
The most effective ways to manage eye health include regular comprehensive eye exams, maintaining a healthy diet, and avoiding smoking. You should discuss any specific concerns about your eye health with your eye care provider.
Is this variant the same as the Y402H polymorphism?
No, rs6792954 is a distinct variant within the CFH gene. While both are located in the same gene and are associated with AMD, they are different genetic markers.
Sources & further reading
Educational information only, last refreshed 10/11/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs6792954?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CFH
This variant in the complement factor H gene is associated with altered regulation of the alternative complement pathway and increased susceptibility to age-related macular degeneration.
This regulatory variant in the CFH locus is linked to complement system dysregulation and is a recognized genetic risk factor for age-related macular degeneration.
Intronic single nucleotide variant in the CFH region associated with susceptibility to age-related macular degeneration (AMD).
Genomic marker in CFH frequently co-inherited in haplotypes modulating risk of late-stage visual loss from macular degeneration.
Intronic marker in CFH forming critical susceptibility haplotypes for choroidal neovascularization and macular atrophy.
Intergenic/intronic variant within the CFH cluster contributing to phenotypic variation in retinal complement activation.